Last reviewed · How we verify
SY-009
At a glance
| Generic name | SY-009 |
|---|---|
| Sponsor | Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus (PHASE2)
- Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus (PHASE1)
- Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus (PHASE1)
- Single Ascending Oral Doses of SY-009 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SY-009 CI brief — competitive landscape report
- SY-009 updates RSS · CI watch RSS
- Suzhou Yabao Pharmaceutical R&D Co., Ltd. portfolio CI